G1 Therapeutics Starts Mid-Stage Bladder Cancer Trial With Cosela

  • G1 Therapeutics Inc GTHX has initiated the PRESERVE 3 Phase 2 study evaluating Cosela (trilaciclib) in patients with untreated, locally advanced, or metastatic urothelial carcinoma (mUC).
  • Cosela will be administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy. Myeloprotection and anti-tumor efficacy endpoints are being assessed in this study. The initial results of this study are expected in the second half of 2022.
  • Patient recruitment in Preserve 3 is now underway. The study will enroll approximately 90 patients.
  • Price Action: GTHX shares are up 1.06% at $21.85 during the market session on the last check Monday.

Posted In: bladder cancerBriefsPhase 2 TrialBiotechNewsHealth CareSmall CapGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.